| Literature DB >> 27895407 |
Hee Yeon Kim1, Chang Wook Kim1, Tae Yeob Kim1, Do Seon Song1, Dong Hyun Sinn1, Eileen L Yoon1, Young Kul Jung1, Ki Tae Suk1, Sang Soo Lee1, Chang Hyeong Lee1, Tae Hun Kim1, Jeong Han Kim1, Hyung Joon Yim1, Sung Eun Kim1, Soon Koo Baik1, Byung Seok Lee1, Jae Young Jang1, Young Seok Kim1, Sang Gyune Kim1, Jin Mo Yang1, Joo Hyun Sohn1, Heon Ju Lee1, Seung Ha Park1, Eun Hee Choi1, Dong Joon Kim1.
Abstract
AIM: To assess the performance of proposed scores specific for acute-on-chronic liver failure in predicting short-term mortality among patients with alcoholic hepatitis.Entities:
Keywords: Acute-on-chronic liver failure; Alcoholic hepatitis; Mortality; Prognosis; Scoring system
Mesh:
Year: 2016 PMID: 27895407 PMCID: PMC5107601 DOI: 10.3748/wjg.v22.i41.9205
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Formulas for scores used in alcoholic hepatitis
| DF[ | 4.6 × [patient’s prothrombin time-control prothrombin time (s)] + total bilirubin (mg/dL) | ||||
| ABIC score[ | (age × 0.1) + [serum bilirubin (mg/dL) × 0.08] + [serum creatinine (mg/dL) × 0.3] + (INR × 0.8) | ||||
| GAHS[ | Age, blood urea nitrogen, white blood cell count, serum bilirubin, and INR; each scored 1-3 | ||||
| MELD score[ | MELD = 3.78 ln[bilirubin (mg/dL)] + 11.20ln(INR)+ 9.57ln[creatinine (mg/dL)] + 6.43 | ||||
| MELD-Na score[ | MELD + 1.59 (135-Na), with maximum and minimum Na of 135 and 120 mEq/L, respectively | ||||
| CLIF-SOFA score[ | 0 | 1 | 2 | 3 | 4 |
| Liver (bilirubin, mg/dL) | < 1.2 | ≥ 1.2 to < 2.0 | ≥ 2.0 to < 6.0 | ≥ 6.0 to < 12.0 | ≥ 12.0 |
| Renal (creatinine, mg/dL) | < 1.2 | ≥ 1.2 to < 2.0 | ≥ 2.0 to < 3.5 | ≥ 3.5 to < 5.0 or use of RRT | ≥ 5.0 |
| CNS (HE grade) | No HE | I | II | III | IV |
| Coagulation (INR) | < 1.1 | ≥ 1.1 to < 1.25 | ≥ 1.25 to < 1.5 | ≥ 1.5 to < 2.5 | ≥ 2.5 or platelet ≤ 20 × 109/L |
| Cardiovascular (hypotension) | MAP ≥ 70 | MAP < 70 | Dopamine ≤ 5 or dobutamine (any dose) | Dopamine > 5 or epi ≤ 0.1 or norepi ≤ 0.1 | Dopamine > 15 or epi > 0.1 or norepi > 0.1 |
| Respiration | |||||
| PaO2/FiO2 | > 400 | > 300 to ≤ 400 | > 200 to ≤ 300 | > 100 to ≤ 200 | ≤ 100 |
| Or SpO2/FiO2 | > 512 | > 357 to ≤ 512 | > 214 to ≤ 357 | > 89 to ≤ 214 | ≤ 89 |
| CLIF-C OF score[ | 1 | 2 | 3 | ||
| Liver (bilirubin, mg/dL) | < 6 | ≥ 6.0 to < 12.0 | ≥ 12 | ||
| Renal (creatinine, mg/dL) | < 2 | ≥ 2.0 to < 3.5 | ≥ 3.5 or RRT | ||
| CNS (HE grade) | 0 | 1-2 | 3-4 | ||
| Coagulation (INR) | < 2.0 | ≥ 2.0 to < 2.5 | ≥ 2.5 | ||
| Cardiovascular (hypotension) | MAP ≥ 70 | MAP < 70 | Vasopressors | ||
| Respiration | |||||
| PaO2/FiO2 | > 300 | ≤ 300 and > 200 | ≤ 200 | ||
| Or SpO2/FiO2 | > 357 | > 214 and ≤ 357 | ≤ 214 | ||
Adrenergic agents administered for at least 1 h (disease are given in μg/kg/min). DF: Discriminant function; ABIC: Age, bilirubin, INR creatinine; GAHS: Glasgow Alcoholic Hepatitis Score; MELD: Model for end-stage liver disease; MELD-Na: Modified MELD including sodium; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; CLIF-C OF: Chronic Liver Failure Consortium Organ Failure score; INR: International normalized ratio; RRT: Renal replacement therapy; HE: Hepatic encephalopathy; MAP: Mean arterial pressure; PaO2: Partial pressure of arterial oxygen; FiO2: Fraction of inspired oxygen; SpO2: Pulse oximetric saturation.
Baseline characteristics of patients
| Age (yr) | 48.8 ± 9.1 | 48.6 ± 9.2 | 48.3 ± 8.1 | 0.865 |
| Men, | 204 (77.3%) | 175 (75.4%) | 29 (90.6%) | 0.070 |
| Presence of cirrhosis, | 240 (90.9%) | 208 (89.7%) | 32 (100%) | 0.092 |
| SIRS, | 76 (28.8%) | 63 (27.2%) | 13 (40.6%) | 0.144 |
| Mean blood pressure (mmHg) | 89.3 ± 15.9 | 90.1 ± 15.1 | 83.5 ± 20.0 | 0.082 |
| WBC count (× 109/L) | 9.6 ± 6.0 | 9.2 ± 5.9 | 12.0 ± 6.7 | 0.013 |
| Platelet count (× 109/L) | 109.2 ± 71.5 | 110.6 ± 72.0 | 98.7 ± 68.0 | 0.377 |
| Albumin (g/dL) | 2.7 ± 0.6 | 2.7 ± 0.5 | 2.3 ± 0.6 | < 0.0001 |
| Bilirubin (mg/dL) | 11.3 ± 8.6 | 10.3 ± 8.0 | 18.7 ± 9.7 | < 0.0001 |
| AST (U/L) | 157.7 ± 86.6 | 160.5 ± 88.4 | 137.3 ± 70.7 | 0.098 |
| ALT (U/L) | 49.9 ± 32.4 | 50.4 ± 33.3 | 46.4 ± 24.6 | 0.514 |
| GGT (U/L) | 428.4 ± 437.5 | 455.4 ± 448.4 | 236.9 ± 290.5 | 0.001 |
| Prothrombin time (s) | 18.0 ± 5.2 | 17.3 ± 3.9 | 22.8 ± 9.6 | 0.004 |
| INR | 1.7 ± 0.6 | 1.6 ± 0.4 | 2.3 ± 0.9 | 0.001 |
| Creatinine (mg/dL) | 1.2 ± 1.5 | 0.9 ± 0.7 | 2.9 ± 3.6 | 0.005 |
| Sodium (mEq/L) | 133.5 ± 6.6 | 133.8 ± 6.3 | 131.1 ± 8.2 | 0.078 |
| DF score | 38.8 ± 28.2 | 34.9 ± 21.6 | 68.4 ± 48.0 | 0.001 |
| ABIC score | 7.5 ± 1.4 | 7.3 ± 1.1 | 9.0 ± 1.9 | < 0.0001 |
| GAHS | 7.4 ± 1.5 | 7.2 ± 1.3 | 9.1 ± 1.6 | < 0.0001 |
| MELD score | 21.6 ± 6.9 | 20.3 ± 5.5 | 30.6 ± 9.1 | < 0.0001 |
| MELD-Na score | 24.3 ± 6.8 | 23.1 ± 5.9 | 32.3 ± 7.2 | < 0.0001 |
| CLIF-SOFA score | 6.8 ± 3.1 | 6.1 ± 2.1 | 11.5 ± 4.6 | < 0.0001 |
| CLIF-C OF score | 7.9 ± 2.0 | 7.4 ± 1.4 | 11.2 ± 2.9 | < 0.0001 |
Data are presented as mean ± SD or n (%). SIRS: Systemic inflammatory response syndrome; WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyltransferase; INR: International normalized ratio; DF: Discriminant function; ABIC: Age, bilirubin, INR, creatinine; GAHS: Glasgow Alcoholic Hepatitis Score; MELD: Model for end-stage liver disease; MELD-Na: Modified MELD including sodium; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; CLIF-C OF: Chronic Liver Failure Consortium Organ Failure.
Figure 1Receiver operating characteristics curve comparison between scoring systems in predicting short-term mortality. A: 28-d mortality; B: 90-d mortality. Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) area under receiver operating characteristics curve (AUROC), 0.86; 95%CI: 0.81-0.90; CLIF Consortium Organ Failure score (CLIF-C OFs) AUROC, 0.89; 95%CI: 0.84-0.92; DF AUROC, 0.79; 95%CI: 0.74-0.84; ABIC AUROC, 0.78; 95%CI: 0.72-0.83; GAHS AUROC, 0.81; 95%CI: 0.76-0.86; MELD AUROC, 0.83; 95%CI: 0.78-0.88; MELD-Na AUROC, 0.83; 95%CI: 0.78-0.88 for 28-d mortality.
Performance characteristics of various scoring systems in predicting 28- and 90-d mortality
| 28-d mortality | ||||||
| CLIF-SOFA | 0.86 (0.81-0.90) | 8 | 78.1% | 79.7% | 34.7% | 96.4% |
| CLIF-C OF | 0.89 (0.84-0.92) | 10 | 68.8% | 91.4% | 52.4% | 95.5% |
| DF | 0.79 (0.74-0.84) | 32 | 81.3% | 50.9% | 18.6% | 95.2% |
| ABIC | 0.78 (0.72-0.83) | 9 | 43.7% | 93.5% | 48.3% | 92.3% |
| GAHS | 0.81 (0.76-0.86) | 9 | 65.6% | 83.2% | 35.0% | 94.6% |
| MELD | 0.83 (0.78-0.88) | 21 | 87.5% | 57.8% | 22.2% | 97.1% |
| MELD-Na | 0.83 (0.78-0.88) | 28 | 68.8% | 80.2% | 32.4% | 94.9% |
| 90-d mortality | ||||||
| CLIF-SOFA | 0.81 (0.76-0.86) | 8 | 66.7% | 84.3% | 54.8% | 89.8% |
| CLIF-C OF | 0.83 (0.78-0.88) | 10 | 52.9% | 94.4% | 73.0% | 87.5% |
| DF | 0.77 (0.71-0.82) | 32 | 78.4% | 53.4% | 32.5% | 89.6% |
| ABIC | 0.78 (0.72-0.83) | 9 | 39.2% | 96.1% | 74.1% | 84.7% |
| GAHS | 0.82 (0.77-0.87) | 9 | 68.6% | 88.8% | 63.6% | 90.8% |
| MELD | 0.81 (0.77-0.87) | 21 | 82.4% | 61.8% | 38.2% | 92.4% |
| MELD-Na | 0.87 (0.82-0.91) | 28 | 66.7% | 87.6% | 60.7% | 90.2% |
AUROC: Area under receiver operating characteristic curve; PPV: Positive predictive value; NPV: Negative predictive value; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; CLIF-C OF: Chronic Liver Failure Consortium Organ Failure; DF: Discriminant function; ABIC: Age, bilirubin, INR, creatinine; GAHS: Glasgow Alcoholic Hepatitis Score; MELD: Model for end-stage liver disease; MELD-Na: Modified MELD including sodium.
Figure 2Cumulative survival of patients in relation to Chronic Liver Failure-Sequential Organ Failure Assessment (A) and Chronic Liver Failure Consortium Organ Failure score (B). CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; CLIF-C OFs: CLIF Consortium Organ Failure score.